1-1 of 1
Zhaomin Zhan, MD
Close
Sort by
Journal Articles

Impact of Molecular Response of Nilotinib (NIL) for BCR/ABL1 Transcripts ≥ 10% with Imatinib (IM) 3 and/or 6 Months By Sokal Risk in Chronic Phase Chronic Myelogenous Leukemia (CML-CP)

Zhijian Cao, MD, Zhaomin Zhan, MD, Jun Ma, MD
Journal: Blood
Blood (2016) 128 (22): 1915.
https://doi.org/10.1182/blood.V128.22.1915.1915
Published: 2016